Clinical Trial

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.
Protocol Amendment History 4 changes
notable Primary completion moved earlier: 2031-04-24 -> 2031-01-14 2026-07-19
minor Completion moved earlier: 2031-04-24 -> 2031-01-14 2026-07-19
notable Sponsor changed: SpringWorks Therapeutics, Inc. -> SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany 2026-05-09
notable Primary completion pushed: 2031-02-28 -> 2031-04-24 2026-04-07
Trial Details
NCT Number NCT07176689
Lead Sponsor SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Conditions Desmoid Tumor, Aggressive Fibromatosis
Enrollment 50 participants
Start Date 2025-09-17
Primary Completion 2031-01-14 (estimated)
Study Completion 2031-01-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-17